Is kisspeptin FDA-approved for women?

No. No kisspeptin product is FDA-approved — not for women, not for men — and the compounded formulation offered here is not FDA-approved either. Compounded medications are prepared by a licensed pharmacy for an individual patient on a prescription and are not reviewed by the FDA for safety, effectiveness, or quality. A licensed provider may still prescribe one where they judge it appropriate.

Does kisspeptin increase libido in women?

That has not been shown. The one trial in women with distressing low sexual desire gave 32 of them a 75-minute infusion inside an MRI scanner and measured brain activity, not desire scores or sexual frequency. Kisspeptin changed activity in regions involved in sexual and emotional processing, and the authors described the result as groundwork for future clinical trials rather than evidence of a treatment effect.

Can kisspeptin affect ovulation or fertility?

Yes, and that is the point of most of the research. Kisspeptin sits directly above the signal that releases an egg, which is why a single injection of kisspeptin-54 was used in place of a standard trigger shot in IVF trials. Anyone who could become pregnant should raise contraception and their reproductive plans at the first visit, because that answer shapes whether kisspeptin makes sense at all.

Is kisspeptin the same as PT-141?

They are different molecules working on different systems. Kisspeptin acts on the reproductive hormone axis in the hypothalamus. PT-141 is bremelanotide, which acts on the brain's melanocortin system. Vyleesi is FDA-approved; compounded PT-141 is not. That approval covers premenopausal women with acquired, generalized low sexual desire, and it rests on two phase 3 trials. A prescriber weighing low desire considers the two very differently.

How often was kisspeptin given in the women's studies?

Spacing mattered more than amount. Twice-daily injections in women whose periods had stopped produced a large hormone response on day one that had almost disappeared by day 14. The same researchers found twice-weekly injections still raised reproductive hormones significantly after eight weeks. Those are findings about study protocols, not a schedule to follow — a prescriber sets frequency for an individual person.

Kisspeptin for Women: What the Research Shows

The honest answer is that kisspeptin for women has been tested in a small number of short hospital studies, and almost every one of them was asking a question about biology rather than about how a woman feels day to day. It has been given to mature eggs during IVF, to wake up hormone signalling in women whose periods had stopped, and once, inside an MRI scanner, to see how it changed the way the brain handled sexual cues. That is close to the whole human picture. It is a real research story. It is also a much smaller one than the marketing around it suggests.

Kisspeptin is a signal rather than a hormone you are topping up. It sits above the reproductive hormones and tells the hypothalamus to start the sequence that ends in estrogen, ovulation and a period. What kisspeptin does walks through that cascade. This page is about what happened when women were actually given it.

What kisspeptin for women has been tested for

Three settings, three different questions, all of them in a hospital.

Maturing eggs during IVF. In a 2014 study at a London fertility unit, 53 women were given a single injection of kisspeptin-54 instead of the usual trigger shot near the end of their cycle. Eggs matured, embryos were transferred in 49 of the 53 women, and 12 had a clinical pregnancy (Jayasena et al., Journal of Clinical Investigation, 2014).

The follow-up matters more. Sixty women at high risk of ovarian hyperstimulation syndrome — a complication where the ovaries over-respond to fertility treatment and, at its worst, becomes dangerous — got kisspeptin-54 as their trigger. Eggs matured in about 19 of every 20 women, and not one developed moderate, severe or critical hyperstimulation (Abbara et al., Journal of Clinical Endocrinology & Metabolism, 2015).

Waking up a quiet hormone axis. Some women stop having periods because the brain turns the reproductive signal down — often after significant weight loss, heavy training, or a long stretch of stress. Doctors call it hypothalamic amenorrhea. Kisspeptin has been given to small groups of these women to see whether the signal could be switched back on. It could, at least at first.

Desire. One trial, 40 premenopausal women with low sexual desire that distressed them, 32 of whom completed both visits. This is the study nearly every seller is gesturing at, so it is worth being precise.

What the desire study measured, and what it didn't

The women each had a 75-minute infusion into a vein — kisspeptin on one visit, a placebo on the other, with neither they nor the researchers knowing which — while a scanner recorded how their brains responded to erotic video and to faces. Kisspeptin changed activity in several regions involved in sexual and emotional processing, and the size of some of those changes tracked with how much distress a woman had reported at the start (Thurston et al., JAMA Network Open, 2022). Nobody reported a side effect.

So the finding is real, and the finding is about brain scans. The trial was not designed to show that women wanted sex more, or felt better weeks later, and the authors said as much — their words were that the results lay foundations for future clinical work. An infusion in a research unit is a long way from a vial in a refrigerator at home.

The contrast with an approved option is instructive. Vyleesi is FDA-approved; compounded PT-141 is not. That approval covers premenopausal women with acquired, generalized low desire, and it rests on two phase 3 trials of about 1,270 women rather than one imaging study. PT-141 is the same molecule, bremelanotide, and how PT-141 works explains its route through the brain's melanocortin system rather than the reproductive axis.

Spacing turned out to matter more than dose

This is the most useful thing the women's research produced, and it almost never comes up in the forums.

Ten women with stopped periods were given kisspeptin injections twice a day for two weeks. On day one the hormone response was large. By day 14 it had almost vanished — the luteinizing hormone rise fell from roughly 24 units to about 2.5 (Jayasena et al., JCEM, 2009). Their pituitaries still answered a different signal perfectly well. They had simply stopped answering this one.

The same group then tried spacing the injections out. Twice weekly for eight weeks kept reproductive hormone levels significantly higher than placebo, with only partial fading of the response (Jayasena et al., Clinical Pharmacology & Therapeutics, 2010).

The reproductive system is built to be nudged in pulses, not held down. Give it a constant signal and it stops listening — which is why more often is not better here, and why the spacing is a clinical decision rather than something to copy off a message board. The form matters too: kisspeptin-10 clears from the blood in about four minutes, and the women's trials above used the longer kisspeptin-54.

The part that matters if you could become pregnant

Kisspeptin sits directly upstream of ovulation. That is not a theoretical risk — it is the exact property that made it useful as an IVF trigger in the studies above.

For a woman who could become pregnant, that turns contraception into a first-visit conversation rather than an afterthought. A prescriber will want to know whether you are trying to conceive, avoiding it, or in fertility treatment already, because the answer changes whether kisspeptin is a reasonable idea at all. The same goes for pregnancy and breastfeeding, where there is no meaningful human safety data to lean on, and for anything you are already taking that acts on the same hormones. Kisspeptin side effects covers the tolerability picture in more detail.

What the 2026 research is actually asking

As of September 6, 2026, the day this article was written, the newest published work on kisspeptin in women is not a treatment trial at all. On August 28, 2026, a team in Turkey reported measurements of the body's own kisspeptin in fluid drawn from the ovaries of 90 women going through IVF — 30 with polycystic ovary syndrome, 30 who developed ovarian hyperstimulation, and 30 who responded normally. Levels rose across those groups in that order and tracked closely with the standard markers of how hard the ovaries were working. The authors were careful to say this reflects ovarian hyperresponsiveness rather than giving a clinic something it could act on (Korkmaz et al., Journal of Assisted Reproduction and Genetics, 2026).

That is a fair snapshot of where the field is. Most current work in women is measuring the body's own kisspeptin to understand conditions like PCOS, not testing a peptide injection against a placebo for symptoms.

How this gets decided

Kisspeptin is dispensed as a compounded medication and is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. Regulatory status is one input into a prescribing decision rather than the whole of it, and a licensed provider may still prescribe a compounded formulation where they judge it appropriate — that decision is between you and your doctor.

What that judgment weighs, for a woman specifically: your cycle, your reproductive plans, contraception, hormone results where there is a reason to check them, and whether your symptoms point at this system at all. Low desire has a long list of causes — sleep, antidepressants, thyroid, a relationship, iron, perimenopause — and most are not fixed one rung up the hormone ladder.

A licensed provider reviews every request, and not everyone qualifies. Being told no is not the process failing; it is the process. It is also the difference between this and an anonymous vial, where nobody reviews anything and nobody is accountable for what is in it.